Mangoceuticals, Inc. (NASDAQ: MGRX) announced on May 27, 2025, groundbreaking results from field studies for its patented antiviral compound, MGX-0024. The studies, conducted by Solice International at Duraiswamy Farm in India, targeted respiratory diseases in chickens, including Newcastle Disease and Chronic Respiratory Disease.
In a large-scale trial, MGX-0024, delivered through drinking water, achieved 100% survival against respiratory illnesses. A second study involving 10,000 chicks treated from 7 days old for 48 days reported no deaths from respiratory diseases, contrasting with an expected 50% mortality rate on a nearby untreated control farm.
MGX-0024, a blend of natural polyphenols and zinc, is also under evaluation for preventing avian flu (H5N1) in a lab study. The results demonstrate MGX-0024's potential as a vaccine- and antibiotic-free solution for poultry health, aligning with global antibiotic restrictions and opening doors to new markets by meeting demand for antibiotic-free poultry.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.